Cardano's ADA ETF Push Ignites Bullish Debate Amid Diverging Price Forecasts
- Grayscale files ADA ETF application, expanding crypto offerings beyond Bitcoin and Ethereum, signaling institutional interest in Cardano. - Technical analysis highlights bullish flag pattern and $1.15 price target, while some analysts forecast 400% gains to $4 by year-end via Elliott Wave projections. - Diverging market views emerge: $0.80 support level is critical for bulls, but resistance near $0.87-$0.90 and retail selling pressure raise bearish concerns. - Rising ADA search volume parallels 2021 leve
Grayscale has filed for a new exchange-traded fund (ETF) focused on Cardano's native token, ADA , with the submission of an S-1 registration document. This move marks another step in the firm’s broader strategy to expand its crypto product lineup to include altcoins, following successful entries in Bitcoin and Ethereum . The filing indicates growing institutional interest in Cardano and the potential for increased market liquidity should the product gain regulatory approval.
Technical indicators for ADA have also drawn attention from traders and analysts. A bullish flag pattern is currently forming on the daily price chart, a configuration that historically has led to significant price surges. If ADA breaks out of its consolidation phase with strong volume, the token could see a 50% price increase, potentially reaching $1.15 from its current level of approximately $0.827. Analysts have noted that the $0.80 support level is crucial in maintaining the bullish outlook, while a move above $0.85 would further validate the pattern.
Meanwhile, some analysts have projected even more aggressive price targets. One analyst from Minswap DEX, using Elliott Wave analysis, has forecasted a near-400% rise in ADA's price, potentially taking the token to $4 by year-end. The analyst's chart indicates a possible wave extension toward this level, supported by Fibonacci Extension targets ranging from $1.47 to $4.14. However, the current trading range of around $0.80 has led to skepticism among some market participants, with critics questioning Cardano's ability to deliver on such expectations despite its ongoing developments and updates.
Interestingly, Cardano's price action coincides with a resurgence in search interest, according to data from Google Trends. Search volume for ADA is currently at the same level as in January 2021, a period marked by a 1,500% price rally. This renewed interest is seen by some as a potential catalyst, especially with broader macroeconomic factors such as Bitcoin’s declining dominance and a weakening US dollar index creating a more favorable environment for altcoins. Analysts are watching whether these conditions can translate into real-world price performance for ADA.
Conversely, not all analysis is bullish. Some reports suggest that ADA is under pressure, with key resistance levels near $0.87–$0.90 and ongoing retail selling intensifying downward momentum. While whale accumulation has been noted, particularly with over 130 million tokens acquired, broader investor sentiment remains cautious. This uncertainty has led some investors to shift capital toward alternative projects such as Remittix, a DeFi platform offering cross-chain solutions for the remittance industry. RTX , Remittix’s native token, has attracted significant attention and is now backed by over 25,000 holders with institutional support growing.
The Grayscale filing and evolving price action suggest that Cardano is gaining renewed attention in both institutional and retail markets. However, whether these developments translate into long-term success will depend on a combination of technical execution, broader market sentiment, and Cardano's ability to deliver on its roadmap of upgrades and innovations. Investors are likely to watch closely for any regulatory approval or significant price movement in the coming months.
Source:

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Convano’s $3 Billion Bitcoin Treasury Play: A High-Risk, High-Reward Macro Bet in a Weak Yen Environment
- Japanese firm Convano Inc. is allocating $3B to Bitcoin, aiming to hedge against yen depreciation and near-zero interest rates by acquiring 21,000 BTC (0.1% of total supply) by 2027. - The leveraged strategy mirrors moves by Metaplanet and MicroStrategy, using equity/debt financing to accelerate crypto accumulation amid Japan's 260% debt-to-GDP ratio and 15% yen depreciation in 2025. - Critics warn of "death spiral" risks: a 30% BTC price drop could erase $900M from Convano's investment, triggering force

BitMine’s 5% Ethereum Supply Play: A New Sovereign Put for Institutional Crypto Exposure
- BitMine Immersion targets 5% of Ethereum's supply ($8.8B) to create a "sovereign put" mechanism stabilizing ETH prices and enhancing institutional utility. - The strategy combines staking yields (4-6% annualized) and a $24.5B equity program to generate compounding treasury growth through a flywheel effect. - Weekly ETH purchases (~190,500 tokens) reinforce Ethereum's deflationary dynamics, reducing downside risk for holders and boosting institutional confidence. - Post-2025 regulatory clarity and Ethereu

Solana's $88M Whale Accumulation and the Road to $250: On-Chain Confidence and Institutional Conviction
- Solana whales accumulated $88M in 3 days, signaling reduced sell pressure and potential $250 price test. - 13 institutions injected $1.72B into Solana treasuries, leveraging 7-8% staking yields amid ETF approval speculation. - SEC's October 2025 ETF decision could unlock $3.8B-$7.2B in institutional capital, mirroring Bitcoin's ETF surge. - Alpenglow upgrades and $553.8M RWA growth support bullish technical indicators, with $500 price targets by year-end.

"Trump-EU Pharma Deal Averts Tariff War, But Leaves Pricing Battle Unresolved"
- The Trump administration and EU agreed on a 15% tariff for brand-name drugs and APIs, with generics exempt, effective September 1, 2025. - The rate, lower than Trump’s initial 250% threat, avoids a tariff war but excludes Section 232 measures for other partners. - European firms face $19B annual costs, prompting stockpiling and U.S. manufacturing shifts, while U.S. consumers may see higher drug prices. - The deal leaves unresolved pricing disputes and supply chain vulnerabilities, with ongoing Section 23

Trending news
MoreCrypto prices
More








